scholarly journals Long‐term evaluation of combined prolonged‐release oxycodone and naloxone in patients with moderate‐to‐severe chronic pain: pooled analysis of extension phases of two Phase III trials

2014 ◽  
Vol 26 (12) ◽  
pp. 1792-1801 ◽  
Author(s):  
M. Blagden ◽  
J. Hafer ◽  
H. Duerr ◽  
M. Hopp ◽  
B. Bosse
Keyword(s):  
Chronic Pain ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Prolonged Release ◽  
Two Phase ◽  
Phase Iii Trials ◽  
Severe Chronic Pain ◽  
Term Evaluation

scholarly journals Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials

Ophthalmology ◽  
2013 ◽  
Vol 120 (10) ◽  
pp. 2013-2022 ◽  
Author(s):  
David M. Brown ◽  
Quan Dong Nguyen ◽  
Dennis M. Marcus ◽  
David S. Boyer ◽  
Sunil Patel ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Phase Iii ◽  
Long Term Outcomes ◽  
Two Phase ◽  
Phase Iii Trials

scholarly journals Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: post hoc analysis

2020 ◽  
Author(s):  
Cesar Margarit Ferri ◽  
Silvia Natoli ◽  
Paz Sanz-Ayan ◽  
Alberto Magni ◽  
Carlos Guerrero ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Phase Iii ◽  
Prolonged Release ◽  
Post Hoc Analysis ◽  
Three Phase ◽  
Sf 36 ◽  
Phase Iii Trials ◽  
Post Hoc

Aims: To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion: Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.

Causes of death in localised prostate cancer: Long term data from two phase III trials

2018 ◽  
Vol 17 (2) ◽  
pp. e1832
Author(s):  
A. Nabid ◽  
N. Carrier ◽  
É. Vigneault ◽  
C. Lemaire ◽  
M.-A. Brassard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Causes Of Death ◽  
Phase Iii ◽  
Two Phase ◽  
Phase Iii Trials ◽  
Term Data

Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance

2019 ◽  
Vol 14 (15) ◽  
pp. 1293-1308
Author(s):  
Joseph S Solomkin ◽  
Angie Sway ◽  
Kenneth Lawrence ◽  
Melanie Olesky ◽  
Sergey Izmailyan ◽  
...  
Keyword(s):  
Pooled Analysis ◽  
Phase Iii ◽  
Two Phase ◽  
Carbapenem Resistant ◽  
Phase Iii Trials ◽  
New Treatment ◽  
Intent To Treat ◽  
Intra Abdominal Infection ◽  
Abdominal Infections ◽  
Cure Rates

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.

Sign in / Sign up

Export Citation Format

Share Document